ReviewJournal of inflammation research2026
Traditional Chinese Medicine Treatment for Coronary Heart Disease: Pathological Mechanisms of Modulating Cell Death Pathways.
Review in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coronary heart disease (CHD) is one of the most prevalent cardiovascular pathologies, with complications significantly increasing mortality rates. The pathogenesis of CHD is complex and multidimensional, and its cellular and molecular basis remains incompletely understood. Recent studies indicate that multiple forms of cell death participate in the initiation and progression of CHD, including inflammation-driven factors (Pyroptosis- Necroptosis- Ferroptosis), context-dependent modulators (Apoptosis- Autophagy), and emerging/hypothetical mechanisms (PANoptosis- Cuproptosis- Disulfidptosis). Meanwhile, traditional Chinese medicine (TCM) is gaining increasing attention in the management of cardiovascular diseases, particularly CHD. This research summarizes the roles of multiple cell death pathways in the pathogenesis of CHD and provides a detailed review and comprehensive analysis of the mechanisms underlying existing experimental studies on TCM formulas and active components used to treat CHD. We highlight representative TCM metabolites and TCM formulas, such as resveratrol, TongMai YangXin Wan, Gualoupi Injection, etc. It concludes that TCM counteracts CHD by inhibiting various cell death pathways. Current basic research primarily focuses on signaling pathways such as PI3K/Akt, TNF, and MAPK. This work provides new insights and approaches for the treatment of CHD and further research. Finally, it identifies current challenges, including unclear compositions of TCM and insufficient validation of mechanisms, and proposes new directions for future research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.